Werewolf Therapeutics, a biotech company, presented its clinically validated technology addressing limitations in potent cancer immunotherapies.
The company's PREDATOR® platform focuses on creating novel, conditionally activated biologics through differentiated masking and linker technology.
Key product candidates include INDUKINE (inducible cytokine) and INDUCER (inducible T cell engager) molecules with promising efficacy and tolerability profiles.
WTX-124 (IL-2)
Potential best-in-class efficacy and tolerability profile observed in Phase 1/1b trial, showing 30% ORR in a subset of melanoma patients.
WTX-330 (IL-12)
Demonstrated anti-tumor activity and improved therapeutic index in FIH study, with enhanced tolerability and efficacy.
- The presentation highlighted Werewolf Therapeutics' progress in developing innovative cancer immunotherapies with the potential to address current limitations in the field.
- Key milestones include upcoming data release for WTX-124 and ongoing efforts to secure strategic partnerships for further development.
Werewolf Therapeutics' focus on novel biologics and promising clinical results positions it as a key player in advancing cancer immunotherapy treatments.